Never too late: Reducing late breast cancer relapse risk

Current Medical Research and Opinion

Volumn 24, Issue 12, 2008, Pages 3295-3305

  Harbeck, Nadia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aromatase inhibitors; Breast cancer; Endocrine responsive; Extended adjuvant therapy; Tamoxifen

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ALLERGY; ALOPECIA; ARTHRALGIA; ASTHENIA; BONE DENSITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DISTANT METASTASIS; DRUG TOLERABILITY; FEMALE; HAIR LOSS; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MYALGIA; NAUSEA; NOTE; OSTEOPOROSIS; OVERALL SURVIVAL; RASH; RISK REDUCTION; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; EUROPE; METASTASIS; MIDDLE AGED; MORTALITY; POSTMENOPAUSE; REVIEW; RISK FACTOR; TIME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EUROPE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TRIAZOLES;

EID: 62349100059     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802470639     Document Type: Note

References (48)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on relapse and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717 (Pubitemid 40719106)
3. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123:21-27 (Pubitemid 40066168)
4. Goldhirsch A, Wood W, Gelber R, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144
5. Saphner T, Tormey DC, Gray R. Annual hazard rates of relapse for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-2746 (Pubitemid 26329660)
6. Kennecke HF, Olivotto IA, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007;18:45-51 (Pubitemid 46152498)
7. Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630-1637 (Pubitemid 41079801)
8. Lamerato L, Havstad S, Gandhi S, et al. Breast cancer relapse and related mortality in US patients with early breast cancer. J Clin Oncol 2005;23(16S):62s [abstract 738]
9. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271 (Pubitemid 41535367)
10. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008;26:1965-1971
11. Jakesz R, Greil R, Gnant M, et al; on behalf of the Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845-53. Erratum in: J Natl Cancer Inst 2008;100:226
12. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690 (Pubitemid 32492809)
13. Delozier T, Spielmann M, Mace-Lesec'h J, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédé ration Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol 2000;18:3507-3512
14. Delozier T, Spielmann M, Janvier M, et al. Optimal duration of adjuvant tamoxifen (TAM) in early breast cancer (EBC): ten year results of a randomized trial (TAM-01) of the FNCLCC Breast Group. Breast Cancer Res Treat 2005;94(Suppl 1):S10 [abstract 14]
15. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996;88:1828-1833 (Pubitemid 26425057)
16. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 2001;30:56-61
17. ATLAS & aTTom: Recruitment completed - treatment and follow-up continue. Atlas Newsletter 10. Clinical Trials Service Unit, Oxford UK. Available at: http://www.ctsu.ox.ac.uk/projects/atlas/newsletters/jan05.pdf. [Last accessed 27 August 2007]
18. Peto R, et al. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women - preliminary results. Breast Cancer Res Treat 2007;100(Suppl 1): Late-breaking abstract 48
19. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br Med J 1995;311:977-980
20. National Cancer Institute. Clinical announcement: adjuvant therapy of breast cancer - tamoxifen update. Bethesda (MD): National Institutes of Health; 1995. Available at: www.nlm.nih.gov/databases/alerts/tamoxifen.html. [Last accessed 27 August 2007]
21. Lu Q, Yue W, Wang J, et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998;50:63-71 (Pubitemid 28438862)
22. Brodie A, Lu Q, Liu Y, et al. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 1999;6:205-210 (Pubitemid 29260053)
23. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606 (Pubitemid 32451796)
24. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802 (Pubitemid 37362955)
25. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-1955
26. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 2004;22(14S) [abstract 847]
27. Goss PE, Ingle JN, Martino S, et al; National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007;25:2006-2011
28. Muss HB. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 2006;100(Suppl 1):S23 [abstract 102]
29. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-3635 (Pubitemid 46630537)
30. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707-715 (Pubitemid 40767090)
31. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-6940 (Pubitemid 46260279)
32. Barghout V, Abetz L, Thomas S, et al. Impact of letrozole on quality of life in post-menopausal women with early breast cancer: does age matter? Breast Cancer Res Treat 2005;94(Suppl 1):S97 [abstract 2040]
33. Abetz L, Barghout V, Thomas S, et al. Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study. Breast Cancer Res Treat 2005;94(Suppl 1):S100 [abstract 2047]
34. National Institute for Health and Clinical Excellence. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. Issue date: November 2006. Available at: www.nice.org/uk/TA112. [Last accessed 27 August 2007]
35. Fleurence R. An introduction to health economics. Pharm J 2003;271:679-681
36. Karnon J, Delea T, Johnston SR, et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006;24:237-250 (Pubitemid 43374376)
37. Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006;12:374-386 (Pubitemid 44063449)
38. Karnon J, di Trapani F, Kaura S. Cost-effectiveness of extended adjuvant letrozole after 5 years of tamoxifen increases with treatment duration. Eur J Cancer Suppl 2007;5:204 [abstract 2.067]
39. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99:295-300 (Pubitemid 44337921)
40. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-629
41. Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) (German Gynaecological Oncology Research Group) 2008. Guidelines Gynäkologische Onkologie Commission Mamma. English version 08.1.0. Adjuvant Endocrine Postmenopausal. Available at: http://www.ago-online.org/index.php?lang= en&site=mamma-guide-08-1-0&topic=mamma-guide. [Last accessed 8 April 2008]
42. Ingle J, Tu D, Shepherd L, et al. NCIC CTG MA.17. Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. J Clin Oncol 2006;24(18S):15s [abstract 549]
43. Goss P. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab 2006;20(Suppl 1):S5-13 (Pubitemid 44882896)
44. Mamounas EP, Lembersky B, Jeong J-H, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2006;7:416-421 (Pubitemid 46157565)
45. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-836 (Pubitemid 350002883)
46. Wengstrom Y, Aapro M, Leto di Priolo S, et al. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: A European study. Breast 2007;16:462-468 (Pubitemid 47500032)
47. Femara® Summary of Product Characteristics; Novartis Pharmaceuticals Ltd. Camberley, Surrey, UK. Available at: http://www.emc.medicines.org.uk [last accessed 4 September 2007]
48. Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer 2005;5(Suppl 2):S41-5